Relapsed or Refractory Marginal Zone B-cell Lymphoma Clinical Trial
Official title:
A Phase II Study of 131I-rituximab for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma
Marginal zone B-cell lymphoma (MZL) is a lymphoma originated from B-cell in lymph node with
variable differentiation status, which is distributed to a variety of organs.
A high response rate and long term survival is possible through surgery or radiation therapy
alone in the case of limited disease. However frequent relapse and progression is observed
despite of long term survival. The treatment after relapse has not been established yet.
So we investigate the efficacy of radioimmunotherapy using 131I-rituximab in refractory or
relapsed patients with MZL.
n/a
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment